S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
MUST WATCH: Unusual 3-second financial maneuver (Ad)
NASDAQ:AVGR

Avinger - AVGR Stock Forecast, Price & News

$1.74
+0.03 (+1.75%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.68
$1.80
50-Day Range
$1.43
$1.85
52-Week Range
$1.40
$19.26
Volume
170,092 shs
Average Volume
144,607 shs
Market Capitalization
$9.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.50

Avinger MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,308.0% Upside
$24.50 Price Target
Short Interest
Healthy
1.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Avinger in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.97) to ($3.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

AVGR stock logo

About Avinger (NASDAQ:AVGR) Stock

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

Avinger Price Performance

Shares of NASDAQ:AVGR traded up $0.03 on Friday, hitting $1.74. The company's stock had a trading volume of 170,092 shares, compared to its average volume of 144,607. The company has a market capitalization of $9.88 million, a PE ratio of -0.30 and a beta of 1.68. The company has a debt-to-equity ratio of 1.24, a current ratio of 4.67 and a quick ratio of 3.78. Avinger has a 1 year low of $1.40 and a 1 year high of $19.26. The company has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $3.36.

Avinger (NASDAQ:AVGR - Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The medical device company reported ($2.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by ($1.12). The firm had revenue of $1.89 million for the quarter, compared to analysts' expectations of $1.89 million. Avinger had a negative net margin of 219.16% and a negative return on equity of 183.34%. During the same period in the prior year, the business posted ($1.40) earnings per share. Sell-side analysts forecast that Avinger will post -4.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on AVGR. StockNews.com began coverage on Avinger in a research note on Thursday. They issued a "sell" rating for the company. B. Riley cut their target price on Avinger from $11.00 to $9.00 in a research note on Wednesday, May 11th.

Receive AVGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter.

AVGR Stock News Headlines

Avinger Reports Second Quarter 2022 Results
Avinger (NASDAQ:AVGR) Now Covered by StockNews.com
Avinger (AVGR) to Release Earnings on Thursday
Avinger stock slides on ~$5M securities offering
Avinger (NASDAQ:AVGR) Coverage Initiated at StockNews.com
StockNews.com Begins Coverage on Avinger (NASDAQ:AVGR)
Avinger Shares Slide After 1Q Miss - MarketWatch
See More Headlines
Receive AVGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter.

AVGR Company Calendar

Last Earnings
11/11/2021
Today
8/13/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVGR
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.50
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+1,308.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-17,410,000.00
Net Margins
-219.16%
Pretax Margin
-185.01%

Debt

Sales & Book Value

Annual Sales
$10.13 million
Book Value
$2.03 per share

Miscellaneous

Free Float
5,640,000
Market Cap
$9.88 million
Optionable
Not Optionable
Beta
1.68














AVGR Stock - Frequently Asked Questions

Should I buy or sell Avinger stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings
or view top-rated stocks.

What is Avinger's stock price forecast for 2022?

2 brokerages have issued 12-month price objectives for Avinger's stock. Their AVGR share price forecasts range from $9.00 to $40.00. On average, they predict the company's stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 1,308.0% from the stock's current price.
View analysts price targets for AVGR
or view top-rated stocks among Wall Street analysts.

How have AVGR shares performed in 2022?

Avinger's stock was trading at $9.00 on January 1st, 2022. Since then, AVGR stock has decreased by 80.7% and is now trading at $1.74.
View the best growth stocks for 2022 here
.

When is Avinger's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our AVGR earnings forecast
.

How were Avinger's earnings last quarter?

Avinger, Inc. (NASDAQ:AVGR) issued its quarterly earnings results on Thursday, November, 11th. The medical device company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.20. The medical device company earned $2.37 million during the quarter, compared to analyst estimates of $2.52 million. Avinger had a negative net margin of 219.16% and a negative trailing twelve-month return on equity of 183.34%. During the same period in the prior year, the business earned ($1.60) EPS.

When did Avinger's stock split?

Avinger's stock reverse split on the morning of Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Avinger own?

When did Avinger IPO?

(AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

What is Avinger's stock symbol?

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

Who are Avinger's major shareholders?

Avinger's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (2.08%) and Renaissance Technologies LLC (0.51%). Insiders that own company stock include Himanshu Patel, James Cullen, Jeffrey M Soinski and Mark Weinswig.
View institutional ownership trends
.

How do I buy shares of Avinger?

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avinger's stock price today?

One share of AVGR stock can currently be purchased for approximately $1.74.

How much money does Avinger make?

Avinger (NASDAQ:AVGR) has a market capitalization of $9.88 million and generates $10.13 million in revenue each year. The medical device company earns $-17,410,000.00 in net income (profit) each year or ($5.73) on an earnings per share basis.

How can I contact Avinger?

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696.

This page (NASDAQ:AVGR) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.